Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients

Frontiers in Endocrinology

Tony R. Merriman¹  Robert Terkeltaub³  Ting Zhao⁴  Lin Han⁶  Hailong Li⁶  Changgui Li⁸  Jie Lu⁸  Xinde Li⁹  Aichang Ji⁹  Zhen Liu⁹  Yuwei He⁹  Shuhui Hu⁹  Zijing Ran⁹  Xiaomei Xue⁹  Lingling Cui⁹  Can Wang⁹ 

[1] Department of Biochemistry, University of Otago, Dunedin, New Zealand;Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China;Department of Medicine, University of California San Diego, La Jolla, CA, United States;Department of Nutrition, The Affiliated Hospital of Qingdao University, Qingdao, China;Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Birmingham, AL, United States;Institute of Metabolic Diseases, Qingdao University, Qingdao, China;San Diego VA Healthcare System, San Diego, CA, United States;Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Qingdao, China;Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, The Affiliated Hospital of Qingdao University, Qingdao, China;

关键词: visceral fat;    gout;    hyperuricemia;    obesity;    urate-lowering therapy;   

DOI  :  10.3389/fendo.2021.724822

来源: DOAJ

【 摘 要 】

ObjectiveTo clarify the relationship between serum urate (SU) decrease and visceral fat area (VFA) reduction in patients with gout.MethodsWe retrospectively analyzed 237 male gout patients who had two sets of body composition and metabolic measurements within 6 months. Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). All patients were from the specialty gout clinic of The Affiliated Hospital of Qingdao University. The multiple linear regression model evaluated the relationship between change in SU [ΔSU, (baseline SU) – (final visit SU)] and change in VFA [ΔVFA, (baseline VFA) – (final visit VFA)].ResultsULT resulted in a mean (standard deviation) decrease in SU level (464.22 ± 110.21 μmol/L at baseline, 360.93 ± 91.66 μmol/L at the final visit, p <0.001) accompanied by a decrease in median (interquartile range) VFA [97.30 (81.15–118.55) at baseline, 90.90 (75.85–110.05) at the final visit, p < 0.001]. By multiple regression model, ΔSU was identified to be a significant determinant variable of decrease in VFA (beta, 0.302; p = 0.001).ConclusionsThe decrease in SU level is positively associated with reduced VFA. This finding provides a rationale for clinical trials to affirm whether ULT promotes loss of visceral fat in patients with gout.

【 授权许可】

Unknown